An agonist of TLR7 with immune response modifying activity, Approved for basal cell carcinoma, In Phase III for VIN and CIN, Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells.
Products > Drug Discovery > Impurities > Dermatology > Imiquimod and Impurities | Products > Drug Discovery > Inhibitor
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。